Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,141,636
  • Shares Outstanding, K 236,854
  • Annual Sales, $ 124,460 K
  • Annual Income, $ -66,070 K
  • EBIT $ -64 M
  • EBITDA $ -63 M
  • 60-Month Beta 0.83
  • Price/Sales 9.17
  • Price/Cash Flow N/A
  • Price/Book 7.02

Options Overview Details

View History
  • Implied Volatility 102.15% ( -8.04%)
  • Historical Volatility 92.95%
  • IV Percentile 82%
  • IV Rank 57.09%
  • IV High 169.26% on 02/22/24
  • IV Low 12.86% on 06/10/24
  • Put/Call Vol Ratio 0.49
  • Today's Volume 2,966
  • Volume Avg (30-Day) 2,698
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 146,010
  • Open Int (30-Day) 138,026

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.01
  • Number of Estimates 7
  • High Estimate 0.04
  • Low Estimate -0.04
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +108.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.32 +11.57%
on 12/18/24
5.87 -17.89%
on 12/06/24
-0.10 (-2.03%)
since 11/20/24
3-Month
4.32 +11.57%
on 12/18/24
7.18 -32.87%
on 09/27/24
-1.31 (-21.37%)
since 09/20/24
52-Week
4.32 +11.57%
on 12/18/24
10.13 -52.42%
on 02/12/24
-1.12 (-18.86%)
since 12/20/23

Most Recent Stories

More News
Insider Sale: President & CEO of $ARDX (ARDX) Sells 25,000 Shares

MICHAEL RAAB, the President & CEO of $ARDX ($ARDX), sold 25,000 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.1% of their...

ARDX : 4.82 (+2.77%)
Insider Sale: Chief Medical Officer of $ARDX (ARDX) Sells 7,366 Shares

Laura A Williams, the Chief Medical Officer of $ARDX ($ARDX), sold 7,366 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.3%...

ARDX : 4.82 (+2.77%)
Insider Sale: See Remarks of $ARDX (ARDX) Sells 7,046 Shares

ELIZABETH A GRAMMER, the See Remarks of $ARDX ($ARDX), sold 7,046 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.7% of their...

ARDX : 4.82 (+2.77%)
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference

ARDX : 4.82 (+2.77%)
Ardelyx Responds to District Court Decision Granting Motion to Dismiss

ARDX : 4.82 (+2.77%)
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

ARDX : 4.82 (+2.77%)
Ardelyx: Q3 Earnings Snapshot

Ardelyx: Q3 Earnings Snapshot

ARDX : 4.82 (+2.77%)
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

ARDX : 4.82 (+2.77%)
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 9.80 (+0.72%)
AMRN : 0.4600 (-1.18%)
ARDX : 4.82 (+2.77%)
ATNM : 1.2900 (+15.18%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 9.80 (+0.72%)
CORT : 51.40 (+0.49%)
ARDX : 4.82 (+2.77%)
ATNM : 1.2900 (+15.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 5.37
2nd Resistance Point 5.17
1st Resistance Point 4.99
Last Price 4.82
1st Support Level 4.61
2nd Support Level 4.41
3rd Support Level 4.23

See More

52-Week High 10.13
Fibonacci 61.8% 7.91
Fibonacci 50% 7.23
Fibonacci 38.2% 6.54
Last Price 4.82
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar